Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma

New England Journal of Medicine

Volumn 377, Issue 19, 2017, Pages 1813-1823

  Long, G V ^a   Hauschild, A ^d   Santinami, M ^f   Atkinson, V ^c   Mandal, M ^g,h   Chiarion Sileni, V ⁱ   Larkin, J ^o   Nyakas, M ^j   Dutriaux, C ^k   Haydon, A ^c   Robert, C ^k   Mortier, L ^l   Schachter, J ⁿ   Schadendorf, D ^e   Lesimple, T ^m   Plummer, R ⁿ   Ji, R ^q   Zhang, P ^p   Mookerjee, B ^p   Legos, J ^p   Kefford, R ^b   Dummer, R ^p   Kirkwood, J M ^r   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁱ VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

^l INSERM   (France)

^m Centre Euge Marquis   (France)

ⁿ SHEBA MEDICAL CENTER   (Israel)

^o FREEMAN HOSPITAL   (United Kingdom)

^p NOVARTIS PHARMA AG   (Switzerland)

^q UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^r UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BINIMETINIB; COBIMETINIB; DABRAFENIB; ENCORAFENIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHILL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DERMATITIS; DIARRHEA; DISTANT METASTASIS FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRY SKIN; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GENE; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYALGIA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE FREE SURVIVAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; ADOLESCENT; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; SKIN TUMOR; SURVIVAL ANALYSIS; TUMOR RECURRENCE; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85033203396     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1708539     Document Type: Article

References (26)

1. National Comprehensive Cancer Network. Clinical practice guidelines in oncology melanoma. V1. 2017 (https://www .nccn .org/professionals/physician-gls/PDF/melanoma .pdf).
2. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidencebased changes in the eighth edition American Joint Committee on Cancer (AJCC) Cancer Staging Manual. CA Cancer J Clin (in press).
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30.
4. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2, 313 patients with stage III melanoma: comparison of nodal micro-metastases versus macrometastases. J Clin Oncol 2010; 28: 2452-9.
5. Amin MB, Edge SB, Greene FL, et al., eds. AJCC cancer staging manual. 8th ed. New York: Springer, 2016.
6. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017; 14: 463-82.
7. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-Analysis. J Natl Cancer Inst 2010; 102: 493-501.
8. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-26.
9. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013; 6: CD008955.
10. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375: 1845-55.
11. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46.
12. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014-23.
13. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-88.
14. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-9.
15. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
16. Bernstein L, Anderson J, Pike MC. Estimation of the proportional hazard in twotreatment-group clinical trials. Biometrics 1981; 37: 513-9.
17. Berry G, Kitchin RM, Mock PA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 1991; 10: 749-55.
18. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of highrisk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522-30.
19. Tarhini AA, Lee SJ, Hodi FS, et al. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus highdose interferon alfa-2b for resected highrisk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms. J Clin Oncol 2017; 35: 9500. abstract.
20. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
21. Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 2016; 34: 871-8.
22. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAFmutant melanoma: A multicentre, doubleblind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-51.
23. Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-Term survival and safety analysis of a phase 3 study. Ann Oncol 2017 May 5 (Epub ahead of print).
24. Robert C, Karaszewska B, Schachter J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer 2015; 51: 3301. abstract.
25. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Ann Oncol 2016; 6: 27. abstract.
26. Weber J, Grob J, Margolin KA, et al. A phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence. J Immunother Cancer 2015; 2: 3. abstract.